$1.320
-0.029 (-2.22%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
NGEN 相似圖表分析預測
Alphio's NGEN stock price prediction model matches the current NervGen Pharma Corp tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $1.33 (+0.41%). The 1-week path is $1.28 (-2.83%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 NervGen Pharma Corp 股票嗎?
Nervgen Pharma Corp. is not a good buy right now. The current price is $1.35, which is significantly below the 52-week high of $6.30, indicating a steep decline of 78.40% year-to-date. Additionally, the RSI is at a very low 21.92, suggesting oversold conditions, but this may not be a strong enough signal to counteract the negative financial performance, including a net income loss of CAD 29,217,233 in Q2 2026. The main risk is the ongoing equity dilution from the recent public offering, which could further depress the stock price.
NGEN 股價於 Thursday 收在 $1.32,此前下跌 -2.22%
NervGen Pharma Corp (NGEN) last closed at $1.3200001, losing -2.22%. These facts feed the 1-day and 1-week NGEN price prediction above.
預測驅動因素
NervGen Pharma Corp(NGEN)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 NGEN 最接近的股票,依相似度排序。
NGEN 季節性分析
相關文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。